Hold Ajanta Pharma target of Rs 318 Nirmal Bang - Moneycontrol.com PDF Print
Moneycontrol.com
To expand its business scope the company is targeting new therapeutic segments namely - Gastroenterology, Orthopedic, Respiratory and Nephrology.” “We believe Ajanta Pharma is an ideal candidate for re-rating considering its brand concentrated business

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.